Addex Therapeutics (ADXN)
(Delayed Data from NSDQ)
$18.74 USD
-0.76 (-3.90%)
Updated Apr 23, 2024 04:00 PM ET
After-Market: $18.18 -0.56 (-2.99%) 6:04 PM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
Balance Sheet
Fiscal Year End for Addex Therapeutics Ltd Sponsored ADR falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 4 | 7 | 22 | 20 | -99,999 |
Receivables | 0 | 0 | 0 | 0 | NA |
Notes Receivable | 0 | 0 | 0 | 0 | NA |
Inventories | 0 | 0 | 0 | 0 | NA |
Other Current Assets | 0 | 0 | 1 | 1 | NA |
Total Current Assets | 5 | 8 | 24 | 21 | NA |
Net Property & Equipment | 0 | 0 | 0 | 0 | NA |
Investments & Advances | 0 | 0 | 0 | 0 | NA |
Other Non-Current Assets | 0 | 0 | 0 | 0 | NA |
Deferred Charges | 0 | 0 | 0 | 0 | NA |
Intangibles | 0 | 0 | 0 | 0 | NA |
Deposits & Other Assets | 0 | 0 | 0 | 0 | NA |
Total Assets | 5 | 9 | 25 | 22 | NA |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | NA |
Accounts Payable | 3 | 3 | 4 | 3 | NA |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | NA |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | NA |
Accrued Expenses | 0 | 0 | 0 | 0 | NA |
Income Taxes Payable | 0 | 0 | 0 | 0 | NA |
Other Current Liabilities | 0 | 0 | 0 | 1 | NA |
Total Current Liabilities | 3 | 3 | 5 | 4 | NA |
Mortgages | 0 | 0 | 0 | 0 | NA |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | NA |
Convertible Debt | 0 | 0 | 0 | 0 | NA |
Long-Term Debt | 0 | 0 | 0 | 0 | NA |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | NA |
Other Non-Current Liabilities | 0 | 0 | 1 | 2 | NA |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | NA |
Total Liabilities | 4 | 4 | 6 | 6 | NA |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | NA |
Common Stock (Par) | 2 | 1 | 54 | 35 | NA |
Capital Surplus | 297 | 282 | 311 | 306 | NA |
Retained Earnings | -401 | -367 | -360 | -335 | NA |
Other Equity | 105 | 95 | 27 | 9 | NA |
Treasury Stock | 1 | 7 | 13 | 0 | NA |
Total Shareholder's Equity | 1 | 5 | 19 | 16 | NA |
Total Liabilities & Shareholder's Equity | 5 | 9 | 25 | 22 | NA |
Total Common Equity | 1 | 5 | 19 | 16 | 0 |
Shares Outstanding | 1.00 | 0.60 | 0.40 | 0.20 | NA |
Book Value Per Share | 1.28 | 8.58 | 46.30 | 77.90 | 0.00 |
Fiscal Year End for Addex Therapeutics Ltd Sponsored ADR falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 4 | 5 | 8 | 6 |
Receivables | NA | 0 | 0 | 0 | 0 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 0 | 1 | 1 | 1 |
Total Current Assets | NA | 5 | 7 | 10 | 7 |
Net Property & Equipment | NA | 0 | 0 | 0 | 0 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 0 | 0 | 0 | 0 |
Total Assets | NA | 5 | 7 | 10 | 8 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 3 | 2 | 3 | 3 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 0 | 0 | 0 | 0 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 0 | 0 | 0 | 0 |
Total Current Liabilities | NA | 3 | 2 | 3 | 3 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 0 | 0 | 0 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 4 | 2 | 3 | 3 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 2 | 2 | 2 | 1 |
Capital Surplus | NA | 297 | 299 | 293 | 288 |
Retained Earnings | NA | -401 | -405 | -395 | -381 |
Other Equity | NA | 105 | 109 | 108 | 98 |
Treasury Stock | NA | 1 | 1 | 1 | 3 |
Total Shareholder's Equity | NA | 1 | 4 | 7 | 4 |
Total Liabilities & Shareholder's Equity | NA | 5 | 7 | 10 | 8 |
Total Common Equity | 0 | 1 | 4 | 7 | 4 |
Shares Outstanding | 1.00 | 1.00 | 0.80 | 0.70 | 0.60 |
Book Value Per Share | 0.00 | 1.28 | 5.58 | 9.73 | 7.33 |